The chief operating officer of Guangshengtang's anti-Covid oral drug clinical trial was approved: it will have a production capacity of 60 million copies
The chief operating officer of Guangshengtang's anti-Covid oral drug clinical trial was approved: it will have a production capacity of 60 million copies https://whatchinareads.com/article/?uid=0bb4507e3d3b11ed99bcc7030b3aab5e
2022-09-26: [Article Link] Significant progress has been made in the development of anti-Covid-19 oral drugs in the Open House (300436).
On the evening of 25 September, the Open House issued an announcement that the innovative drug control subsidiary Fujian Guangsheng Biotech Co. Ltd. (hereinafter referred to as Hiroshi) had
Please
sign in to continue reading and access original article links of locked articles.
Subscribe now for full access.